Investigation Report on China Anastrozole Market, 2010-2019
As a non-steroidal aromatase-inhibiting, anastrozole works by inhibiting the synthesis of estrogen in post-menopausal women which can increase the severity of breast cancer. Besides, anastrozole has little influence on adrenocortical steroid or aldosterone.
Originally developed by AstraZeneca, anastrozole was approved by FDA as the second-line medicine for breast cancer in 1995 and later in 2000 became the first-line drug. In 2002, it was approved as the therapy for postmenopausal women with localized breast cancer which is ER positive.
The incidence of breast cancer has kept growing since the 1970s in the world. With decreasing fertility rate, environmental changes, increasing pressure and growing number of women aged 50-54 who face greater risk of breast cancer, the incidence of breast cancer in China grows at a rate which is 1-2% higher than that in other countries and doubles that of the world average. As the malignant tumor with the highest incidence, breast cancer will report 2.5 million cases by 2021 in China. Hence a huge market for anastrozole.
The demand for anastrozole is gradually growing. According to CRI’s market survey, anastrozole sales has went up slightly to CNY 184 million in 2014 with CAGR during the period of 2010-2014 reaching 4.89%. And AstraZeneca (US), Yangtze River Pharmaceutical Group, Huapont Pharm, Wanma Group and Hisun occupy the market, among which AstraZeneca (US) had the largest market share of about 92% for sales value in 2014.
Readers can get at least the following information through this report:
market size of anastrozole in China
competitive landscape of anastrozole market in China
price of anastrozole made by different enterprises in China
market outlook of anastrozole in China
The author suggests the following groups of people purchase this report:
manufacturers of anti-tumor drugs
investors/research institutions interested in Chinese medicine market
-any interest in Chinese medicine market, please contact CRI for customized survey service
Please Note: All reports from China Research and Intelligence are written in Chinese, then translated to English. This process takes approximately 5 business days from the date the order is placed